These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 27196586)

  • 1. Treatment scale-up to achieve global HCV incidence and mortality elimination targets: a cost-effectiveness model.
    Scott N; McBryde ES; Thompson A; Doyle JS; Hellard ME
    Gut; 2017 Aug; 66(8):1507-1515. PubMed ID: 27196586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reaching hepatitis C virus elimination targets requires health system interventions to enhance the care cascade.
    Scott N; Doyle JS; Wilson DP; Wade A; Howell J; Pedrana A; Thompson A; Hellard ME
    Int J Drug Policy; 2017 Sep; 47():107-116. PubMed ID: 28797497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modelling the elimination of hepatitis C as a public health threat in Iceland: A goal attainable by 2020.
    Scott N; Ólafsson S; Gottfreðsson M; Tyrfingsson T; Rúnarsdóttir V; Hansdottir I; Hernandez UB; Sigmundsdóttir G; Hellard M
    J Hepatol; 2018 May; 68(5):932-939. PubMed ID: 29274408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of treating chronic hepatitis C virus with direct-acting antivirals in people who inject drugs in Australia.
    Scott N; Iser DM; Thompson AJ; Doyle JS; Hellard ME
    J Gastroenterol Hepatol; 2016 Apr; 31(4):872-82. PubMed ID: 26514998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness and cost-effectiveness of interventions targeting harm reduction and chronic hepatitis C cascade of care in people who inject drugs: The case of France.
    Cousien A; Tran VC; Deuffic-Burban S; Jauffret-Roustide M; Mabileau G; Dhersin JS; Yazdanpanah Y
    J Viral Hepat; 2018 Oct; 25(10):1197-1207. PubMed ID: 29660211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What is required for achieving hepatitis C virus elimination in Singapore? A modeling study.
    Chaillon A; Thurairajah PH; Hsiang JC; Martin NK
    J Gastroenterol Hepatol; 2021 Apr; 36(4):1110-1117. PubMed ID: 32777859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimating the cost-effectiveness of needle-syringe programs in Australia.
    Kwon JA; Anderson J; Kerr CC; Thein HH; Zhang L; Iversen J; Dore GJ; Kaldor JM; Law MG; Maher L; Wilson DP
    AIDS; 2012 Nov; 26(17):2201-10. PubMed ID: 22914579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of the HepCATT intervention in specialist drug clinics to improve case-finding and engagement with HCV treatment for people who inject drugs in England.
    Ward Z; Reynolds R; Campbell L; Martin NK; Harrison G; Irving W; Hickman M; Vickerman P
    Addiction; 2020 Aug; 115(8):1509-1521. PubMed ID: 31984606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of hepatitis C virus (HCV) elimination strategies among people who inject drugs (PWID) in Tijuana, Mexico.
    Marquez LK; Fleiz C; Burgos JL; Cepeda JA; McIntosh C; Garfein RS; Kiene SM; Brodine S; Strathdee SA; Martin NK
    Addiction; 2021 Oct; 116(10):2734-2745. PubMed ID: 33620750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of scaling-up HCV prevention and treatment in the United States for people who inject drugs.
    Barbosa C; Fraser H; Hoerger TJ; Leib A; Havens JR; Young A; Kral A; Page K; Evans J; Zibbell J; Hariri S; Vellozzi C; Nerlander L; Ward JW; Vickerman P
    Addiction; 2019 Dec; 114(12):2267-2278. PubMed ID: 31307116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health outcomes and cost-effectiveness of diversion programs for low-level drug offenders: A model-based analysis.
    Bernard CL; Rao IJ; Robison KK; Brandeau ML
    PLoS Med; 2020 Oct; 17(10):e1003239. PubMed ID: 33048929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is hepatitis C virus elimination possible among people living with HIV and what will it take to achieve it?
    Martin NK; Boerekamps A; Hill AM; Rijnders BJA
    J Int AIDS Soc; 2018 Apr; 21 Suppl 2(Suppl Suppl 2):e25062. PubMed ID: 29633560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessing the cost-effectiveness of treating chronic hepatitis C virus in people who inject drugs in Australia.
    Visconti AJ; Doyle JS; Weir A; Shiell AM; Hellard ME
    J Gastroenterol Hepatol; 2013 Apr; 28(4):707-16. PubMed ID: 23173753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Upscaling prevention, testing and treatment to control hepatitis C as a public health threat in Dar es Salaam, Tanzania: A cost-effectiveness model.
    Scott N; Mohamed Z; Rwegasha J; Mbwambo J; Lemoine M; Hellard M
    Int J Drug Policy; 2021 Feb; 88():102634. PubMed ID: 31882272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness and cost-effectiveness of nationwide campaigns for awareness and case finding of hepatitis C targeted at people who inject drugs and the general population in the Netherlands.
    Helsper CW; Janssen MP; van Essen GA; Croes EA; van der Veen C; de Wit AG; de Wit NJ
    Int J Drug Policy; 2017 Sep; 47():117-125. PubMed ID: 28826994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elimination of hepatitis C virus in Germany: modelling the cost-effectiveness of HCV screening strategies.
    Krauth C; Rossol S; Ortsäter G; Kautz A; Krüger K; Herder B; Stahmeyer JT
    BMC Infect Dis; 2019 Dec; 19(1):1019. PubMed ID: 31791253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic evaluation of the hepatitis C elimination strategy in Greece in the era of affordable direct-acting antivirals.
    Gountas I; Sypsa V; Papatheodoridis G; Souliotis K; Athanasakis K; Razavi H; Hatzakis A
    World J Gastroenterol; 2019 Mar; 25(11):1327-1340. PubMed ID: 30918426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modeling indicates efficient vaccine-based interventions for the elimination of hepatitis C virus among persons who inject drugs in metropolitan Chicago.
    Echevarria D; Gutfraind A; Boodram B; Layden J; Ozik J; Page K; Cotler SJ; Major M; Dahari H
    Vaccine; 2019 May; 37(19):2608-2616. PubMed ID: 30962092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential cost-effectiveness of supervised injection facilities in Toronto and Ottawa, Canada.
    Enns EA; Zaric GS; Strike CJ; Jairam JA; Kolla G; Bayoumi AM
    Addiction; 2016 Mar; 111(3):475-89. PubMed ID: 26616368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health and economic benefits of achieving hepatitis C virus elimination in Pakistan: A modelling study and economic analysis.
    Lim AG; Scott N; Walker JG; Hamid S; Hellard M; Vickerman P
    PLoS Med; 2021 Oct; 18(10):e1003818. PubMed ID: 34665815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.